12:00 AM
 | 
Apr 22, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Scenesse afamelanotide regulatory update

Clinuvel said EMA needs more time to review an MAA for Scenesse afamelanotide for prophylactic treatment of erythropoietic protoporphyria (EPP). The company, which submitted the MAA...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >